ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Anacor Extends R&D Deals

by Ann M. Thayer
September 12, 2011 | APPEARED IN VOLUME 89, ISSUE 37

Anacor Pharmaceuticals has expanded R&D collaborations for its boron-based anti-infective agents. GlaxoSmithKline now has the option to obtain rights related to the bacterial enzyme target leucyl-tRNA synthetase and to add programs for tuberculosis and malaria. In return, Anacor will receive $5.0 million up front and R&D and milestone payments of up to $11.3 million through 2012. Separately, the U.S. government just granted GSK up to $94 million to support, among other things, the development of an Anacor-discovered antibiotic. In malaria, GSK has the option to acquire Anacor’s lead compound, AN3661. Anacor has just extended an agreement with the Medicines for Malaria Venture to start clinical development of AN3661.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment